




RealRate

PHARMACEUTICAL 2022

Evoke Pharma Inc
Rank 392 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 1.9% points. The greatest weakness of Evoke Pharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 134% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	10,561	Assets	10,573
Cost of Goods Sold	0	Liabilities	7,018
Intangible Assets	0	Expenses	9,770
Liabilities, Current	1,406	Revenues	1,618
Liabilities, Non-Current	5,612	Stockholders Equity	3,555
Other Assets	12	Net Income	-8,538
Other Compr. Net Income	0	Comprehensive Net Income	-8,538
Other Expenses	328	BaseVar	14,683
Other Liabilities	0	ECR before LimitedLiability	-9.0%
Other Net Income	-386	Economic Capital Ratio	141%
Other Revenues	1,618		
Property and Equipment	0		
Research and Development	590		
Selling, General and Administrative Expense	8,851		